ReviewCancer science2015
Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects.
Review in Cancer science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.
- The prognostic values of estrogen receptor alpha and beta in patients with gastroesophageal cancer: A meta-analysis.Medicine · 2019Pooled it
- Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role.International journal of molecular sciences · 2018Trial
- Effects of Transdermal Testosterone Gel or an Aromatase Inhibitor on Prostate Volume in Older Men.The Journal of clinical endocrinology and metabolism · 2016Trial
- Article
- Jaboticaba peel extract limits castration-resistant prostate cancer aggressiveness by counteracting EMT through steroid hormone and TGF-β signaling modulation.Journal of molecular histology · 2026Article
- Combinatorial Synthesis of Tetrasubstituted Alkenes and Related Compounds with Potential Anticancer Activity.Combinatorial chemistry & high throughput screening · 2026Article
- A Dynamic Shift in Estrogen Receptor Expression During Granulosa Cell Differentiation in the Ovary.Endocrinology · 2025Article
- Proteogenomic Landscape of Breast Ductal Carcinoma Reveals Tumor Progression Characteristics and Therapeutic Targets.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.BMC cancer · 2024Article
- Machine learning-assisted high-content imaging analysis of 3D MCF7 microtissues for estrogenic effect prediction.Scientific reports · 2024Article
- The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy.Research and reports in urology · 2024Review
- Design and Pharmacophore Study of Triazole Analogues as Aromatase Inhibitors.Anti-cancer agents in medicinal chemistry · 2024Article
- Review
- Functionalized liposomes for targeted breast cancer drug delivery.Bioactive materials · 2023Review
- Review
- Review
- Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms.Frontiers in oncology · 2023Review
- Epigenetic restoration and activation of ERβ: an inspiring approach for treatment of triple-negative breast cancer.Medical oncology (Northwood, London, England) · 2022Article
- Andrographolide Exhibits Anticancer Activity against Breast Cancer Cells (MCF-7 and MDA-MB-231 Cells) through Suppressing Cell Proliferation and Inducing Cell Apoptosis via Inactivation of ER-α Receptor and PI3K/AKT/mTOR Signaling.Molecules (Basel, Switzerland) · 2022Article
- Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast and prostate cancers are among the most common of all cancers. They are referred to as hormone-dependent cancers, because estrogen and androgen are involved in their development and growth. The effects of these hormones are mediated by their respective receptors, estrogen receptor (ER) α and androgen receptor. Around 18 years ago, a second ER, ERβ, which has a very similar structure to ERα, was discovered. Its function has been investigated using a variety of methods and biological systems, leading to our present understanding that ERβ can interact with or inhibit ERα and androgen receptor function directly and/or indirectly, suppress cell growth, and influence responsiveness to endocrine therapy. In order to apply the "inhibition of cell growth" function to cancer treatment, several specific ERβ agonists have been synthesized and are being tested for effectiveness in cancer treatment. We need to keep our eyes on ERβ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.